This agreement grants Qilu exclusive rights to develop, manufacture, enhance, utilise and commercialise Albipagrastim alfa for Injection in Greater China including Chinese Mainland, Macau, Hong Kong and Taiwan.
Paediatric HGG, including ependymoma, are not only rare but also very difficult to treat, with current standard care failing to prevent recurrence and with five-year survival rates. Reyobiq
This follows a similar endorsement by the US Food and Drug Administration (FDA). Sanfilippo syndrome type B is an autosomal recessive disease marked by mutations in the N-acetyl-alpha-glucosaminidase
This collaboration appoints Optime Care as the exclusive specialty pharmacy provider for the newly FDA-approved tablets, ensuring the medication’s availability to patients. Optime Care general manager Bill Bertetto
This new small molecule is designed for prostate cancer imaging and treatment. The FDA’s approval allows Archeus to begin a Phase I clinical study targeting metastatic castration-resistant prostate
PiaSky will be given as the first monthly subcutaneous therapy for adults and adolescents aged 13 years or more with a minimum body weight of 40kg. Patients have
The partnership grants Daewoong access to Salipro’s expertise and platform specifically designed for stabilising challenging membrane proteins such as G protein-coupled receptors (GPCRs), ion channels, and transporters. The
MRT-8102 is a NEK7-directed molecular glue degrader being developed to treat inflammatory diseases driven by the NLRP3 inflammasome and IL-1β. Monte Rosa Therapeutics CEO Markus Warmuth said: “The
Under the agreement, Neowise will be eligible for an upfront payment and will also receive future milestone payments. These payments are contingent upon reaching specific development, regulatory, and
Duvyzat must be administered alongside corticosteroids and is not limited by the patient’s specific genetic mutation. The decision is applicable across all 27 EU member states, as well
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.